In Vivo Star Anti-Mouse VEGF Antibody
英诺赛图(InnoCyto)的 In Vivo Star Anti-Mouse VEGF Antibody(克隆 G6-31) 为鼠源 IgG2a Kappa 抗体,靶向 Mouse。提供 1 mg、5 mg、25 mg 规格,目录价 ¥1,085 起,仅供科研使用(RUO)。
01产品图片

02产品简介
英诺赛图(InnoCyto)的 In Vivo Star Anti-Mouse VEGF Antibody(克隆 G6-31) 为鼠源 IgG2a Kappa 抗体,靶向 Mouse。提供 1 mg、5 mg、25 mg 规格,目录价 ¥1,085 起,仅供科研使用(RUO)。
03产品介绍
规格与货号
512901 | 1 mg | ¥1,085
512902 | 5 mg | ¥2,712
512903 | 25 mg | ¥7,458
513001 | 1 mg | ¥1,085
513002 | 5 mg | ¥2,712
513003 | 25 mg | ¥7,458
513101 | 1 mg | ¥1,085
513102 | 5 mg | ¥2,712
513103 | 25 mg | ¥7,458
Product Details
Application|ELISA, WB, Flow cytometry, IHC, ICC, animal model study
Target Name|Vascular endothelial growth factor, VEGF-A, VEGFA, VEGF
Product Description|In Vivo Grade Recombinant Anti-mouse VEGF Monoclonal Antibody
Regulatory Status|RUO
Endotoxin
Storage Conditions|4ºC
Recommended Usage|This product is suitable for in vivo animal use. Optimal amounts need to be determined empirically for each experiment.
See All Formats|Clone G6-31
Background Information
Vascular Endothelial Growth Factor (VEGF) is a potent signaling protein that plays a central role in angiogenesis - the formation of new blood vessels from existing vasculature. It is essential during embryonic development, wound healing, and tissue regeneration, serving as a key regulator of vascular permeability and endothelial cell proliferation. In adults, VEGF facilitates physiological angiogenesis in the ovary, endometrium, and skeletal muscle but also contributes to various pathological processes when dysregulated.
Structurally, VEGF belongs to a larger family of growth factors that includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, and Placental Growth Factor (PlGF). The prototype, VEGF-A, is a homodimeric glycoprotein composed of two approximately 23-kDa subunits linked by disulfide bonds. Alternative splicing of the VEGF-A gene gives rise to multiple isoforms (such as VEGF121, VEGF165, and VEGF189), each differing in heparin-binding affinity and bioavailability. These isoforms allow for fine-tuned regulation of angiogenic signaling within different tissues and physiological contexts.
VEGF family members function by binding to high-affinity tyrosine kinase receptors on endothelial cells: VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3 (Flt-4), in conjunction with co-receptors like neuropilins (NRP-1 and NRP-2). Among these, VEGFR-2 mediates most of the pro-angiogenic effects, triggering intracellular signaling cascades such as the PI3K/Akt and MAPK pathways, which promote endothelial cell survival, proliferation, migration, and vascular permeability.
Dysregulation of VEGF signaling is implicated in numerous diseases. Overexpression of VEGF drives pathological angiogenesis in cancers, diabetic retinopathy, and age-related macular degeneration (AMD). Tumors exploit VEGF signaling to establish a blood supply, providing oxygen and nutrients necessary for growth and metastasis. Conversely, insufficient VEGF expression can lead to impaired wound healing and ischemic diseases due to poor blood vessel development.
Therapeutically, VEGF and its receptors are major targets in modern medicine. Anti-VEGF therapies aim to inhibit excessive angiogenesis and restore vascular balance. Bevacizumab (Avastin), a monoclonal antibody against VEGF-A, was the first anti-angiogenic therapy approved for cancer treatment. Other agents, such as ranibizumab (Lucentis) and aflibercept (Eylea), are widely used in ophthalmology to treat AMD and diabetic macular edema by preventing abnormal vascular leakage and neovascularization in the retina. Additionally, small-molecule inhibitors targeting VEGFR tyrosine kinases, such as sunitinib, sorafenib, and pazopanib, are employed in cancer therapy to block downstream VEGF signaling pathways. Collectively, VEGF-targeted therapies have transformed the treatment landscape of cancer and ocular diseases but continue to be refined to minimize toxicities and resistance mechanisms.
Data Sheets
Cat # Size Price Quantity 5131011 mg Add to Cart5131025 mg Add to Cart51310325 mg Add to Cart
04完整参数表
参数由厂商资料整理,采购前请以最终报价单与技术协议为准。
05荣誉与资质
该品牌暂未上传荣誉证书与资质文件。以下是平台可核验的公开信息,未上传项如实标注,不做推断。
- 营业执照未上传
- 品牌授权未上传
- 产品检测报告未上传
- 会员身份
- 收费会员
- 经营身份
- 原厂
- 成立年份
- 2020 年
- 所在地
- 上海
- 收录条目
- 1865 个
- 平台核验
- 平台代管
06品牌与供应商
InnoCyto(上海英诺赛图生物科技有限公司)致力于通过开发高质量细胞分析试剂,加速科学发现进程。公司为研究人员提供细胞层面探索所需的工具,推动免疫学、肿瘤学等多领域的研究创新。 核心团队拥有丰富的行业经验,曾参与全球头部生命科学公司的标杆项目搭建,深刻理解工业界与学术研究的前沿需求。试剂从设计之初即以精确性、一致性、高性能为核心标准,让科学家能把精力集中在最核心的研究工作上。 公司将深厚的科学积累与对品质的严格承诺相结合,力争成为全球研究人员信赖的合作伙伴。产品线覆盖经验证的一抗与二抗、同型对照、生物类似药抗体、重组蛋白、细胞因子、免疫检测试剂盒及配套试剂,并提供重组蛋白/抗体表达与标记偶联服务。
品牌资料由厂商公开信息与授权渠道核对整理;条目参数与价格以最终报价单为准。
07同类条目
同一子类内的条目才具备可比性。跨子类比较参数通常没有意义。
08同品牌其他条目
上海英诺赛图 在本目录共 1865 个条目,除本条外还有:
科研在线(TeleVM). In Vivo Star Anti-Mouse VEGF Antibody(513101)[EB/OL]. 产品目录, 2026-11-12. https://www.suprotek.cn/products/item/in-vivo-star-anti-mouse-vegf-antibody-513101.html.
TeleVM. (2026, November 12). In Vivo Star Anti-Mouse VEGF Antibody(513101). 产品目录. https://www.suprotek.cn/products/item/in-vivo-star-anti-mouse-vegf-antibody-513101.html
@misc{biocsp_item_in_vivo_star_anti_mouse_vegf_antibody_513101,
title = {In Vivo Star Anti-Mouse VEGF Antibody(513101)},
author = {{科研在线}},
year = {2026},
howpublished = {产品目录},
note = {更新于 2026-11-12,产品目录},
url = {https://www.suprotek.cn/products/item/in-vivo-star-anti-mouse-vegf-antibody-513101.html}
}
GB/T 7714 用于中文论文与报告;APA 7 用于英文期刊;BibTeX 可直接导入 Zotero、EndNote 或 LaTeX。
许可:CC BY-NC 4.0 · 转载注明来源